Mibelas 24 Fe Kit
Product Images NDC 68180-911

12 FDA label images from Lupin Pharmaceuticals, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Mibelas 24 Fe (NDC 68180-911). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Lupin Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (4da34ed3 8449 46a5 B662 B30042df51eb 01)

Figure 1 (4da34ed3 8449 46a5 B662 B30042df51eb 01)
A forest plot titled 'Relevant Studies of Risk of Breast Cancer with Combined Oral Contraceptives' showing effect estimates (OR, RR, HR) with confidence intervals for different studies comparing risk between ever COC use vs. never use and current COC use vs. never use. The horizontal axis ranges from -1.50 to 2.00, plotting individual study risk estimates and confidence intervals around 1.0 (null effect).*
FDA Label Image

Ethinyl Estradiol (4da34ed3 8449 46a5 B662 B30042df51eb 02)

Ethinyl Estradiol (4da34ed3 8449 46a5 B662 B30042df51eb 02)
Chemical structure of the active ingredient depicted in the image, showing a steroidal core with hydroxyl groups and a terminal ethynyl group, consistent with the structure of ethinyl estradiol.*
FDA Label Image

Norethindrone Acetate (4da34ed3 8449 46a5 B662 B30042df51eb 03)

Norethindrone Acetate (4da34ed3 8449 46a5 B662 B30042df51eb 03)
Chemical structure diagram of the active ingredient found in Mibelas 24 Fe by Lupin Pharmaceuticals, Inc. The structure shows a steroid-like backbone with a ketone group, an acetoxy group, and an ethynyl group attached, representing the molecular features of the compound.*
FDA Label Image

Figure 2 (4da34ed3 8449 46a5 B662 B30042df51eb 04)

Figure 2 (4da34ed3 8449 46a5 B662 B30042df51eb 04)
A line graph showing norethindrone concentration (pg/mL) over time (hours). The concentration peaks sharply near the start and declines gradually, with data points spanning from 0 to 36 hours and error bars indicating variability at each measurement.*
FDA Label Image

Figure 4 (4da34ed3 8449 46a5 B662 B30042df51eb 05)

Figure 4 (4da34ed3 8449 46a5 B662 B30042df51eb 05)
A line graph showing ethinyl estradiol concentration (pg/mL) over time (hours). Concentration peaks early within hours after administration, then gradually declines over 36 hours with error bars indicating variability at each time point.*
FDA Label Image

Image (4da34ed3 8449 46a5 B662 B30042df51eb 06)

FDA Label Image

Figure 5 (4da34ed3 8449 46a5 B662 B30042df51eb 07)

Figure 5 (4da34ed3 8449 46a5 B662 B30042df51eb 07)
A chart showing pregnancy probabilities per 100 women in one year linked to contraceptive methods. It categorizes methods from fewer pregnancies (implants, injections, intrauterine devices, sterilization) to more pregnancies (no birth control). Intermediate methods include birth control pills, skin patch, vaginal ring with hormones, condoms, diaphragm, and behavioral methods like abstinence during fertile days, spermicide, and withdrawal.*
FDA Label Image

Blister Image (4da34ed3 8449 46a5 B662 B30042df51eb 08)

Blister Image (4da34ed3 8449 46a5 B662 B30042df51eb 08)
An illustrated medication schedule for Mibelas 24 Fe organized in a 4-week layout. The diagram shows circles arranged by days of the week—Sunday through Saturday—with arrows indicating the daily pill-taking sequence. The starting point is marked at Sunday of Week 2 and the progression flow continues through Weeks 2, 3, and 4, guiding the user on a 28-day cycle.*
FDA Label Image

Image (4da34ed3 8449 46a5 B662 B30042df51eb 09)

FDA Label Image

Carton Label (4da34ed3 8449 46a5 B662 B30042df51eb 10)

Carton Label (4da34ed3 8449 46a5 B662 B30042df51eb 10)
Packaging label for Mibelas 24 Fe chewable tablets by Lupin Pharmaceuticals, Inc. This product contains norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets, with strengths of 1 mg and 0.02 mg respectively. The label states Rx only, provides 24 days of active therapy, and includes 3 blisters of 28 tablets each. Manufactured in India and distributed by Lupin Pharmaceuticals, Inc.*
FDA Label Image

Pouch Label (4da34ed3 8449 46a5 B662 B30042df51eb 11)

Pouch Label (4da34ed3 8449 46a5 B662 B30042df51eb 11)
Mibelas 24 Fe chewable tablets packaging label shows the active ingredients norethindrone acetate 1 mg and ethinyl estradiol 0.02 mg along with ferrous fumarate tablets. The label states this product provides 24 days of active therapy and contains one blister of 28 tablets. Manufactured by Lupin Pharmaceuticals, Inc., the label includes usage warnings and regulatory information, with purple gradient background and barcodes.*
FDA Label Image

Blister Label (4da34ed3 8449 46a5 B662 B30042df51eb 12)

Blister Label (4da34ed3 8449 46a5 B662 B30042df51eb 12)
Mibelas 24 Fe chewable tablets packaging label showing the lidding foil side with the proprietary name, active ingredients norethindrone acetate and ethinyl estradiol, strength 1 mg/0.02 mg, and manufacturer Lupin Limited, India. The label also includes storage instructions, barcode, lot number, and expiration date fields, along with a monthly self-breast exam reminder. The reverse forming foil side displays a weekly pill calendar for weeks 2 to 4 with days of the week and arrows for dosing guidance.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.